产品
编 号:F622093
分子式:C24H32Cl3N7O
分子量:540.92
产品类型
结构图
CAS No: 1786438-30-9
联系客服
产品详情
生物活性:
(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect. (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K.
体内研究:
(R)- CR8 trihydrochloride 三盐酸盐 (5 mg/kg;腹腔注射) 在组织学评估中导致第 28 天的损伤大小显著减小。Animal Model:Adult (10 to 12 weeks old) male Sprague-Dawley rats (310 to 330?g)
Dosage:5?mg/Kg
Administration:i.p.
Result:Resulted in a significant reduction in lesion size.
体外研究:
(R)- CR8 trihydrochloride (CR8) trihydrochloride (0.1-100 μM;48 小时) 是一种有效的凋亡细胞死亡诱导剂,对 SH-SY5Y 细胞系的 IC50 为 0.49 μM。 (R)- CR8 trihydrochloride trihydrochloride (0.25-10 μM) 剂量依赖性地诱导聚-(ADP-核糖) 聚合酶 (PARP) 裂解。 (R)- CR8 trihydrochloride 三盐酸盐的 CDK 结合形式具有暴露于溶剂中的吡啶基部分,可诱导 CDK12-细胞周期蛋白 K 和 CuL4 衔接蛋白 DDB1 之间形成复合物,绕过对 a 的要求底物受体和呈递细胞周期蛋白 K 以进行泛素化和降解.?